TargetCancer Foundation Enrolls First Patient to Decentralized, Rare Cancer TRACK Study

Nov

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov

Featured Webinar

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov

Featured Webinar

The Tumor Neighborhood Watch: How Spatial Architecture and Cellular Neighborhoods Correlate to Colorectal Cancer Outcomes

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context.

Menu

TargetCancer Foundation Enrolls First Patient to Decentralized, Rare Cancer TRACK Study

To read the full story....

Breaking News

Broad Genetic Testing Uncovers Additional Risk Variants in Cancer Patients, Study Finds

VieCure, TD2 Enter Partnership to Improve Access to Precision Oncology Trials

Avatamed, Macrogen to Launch Precision Oncology Service in Sountheast Asia, Europe

Atyr Pharma, Medical University of South Carolina Partner to Develop NRP2-Targeted Antibodies

Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC

Epic Sciences, Predicine to Offer Liquid Biopsy Service for Biopharma Customers

Featured White Papers

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

The Tumor Neighborhood Watch: How Spatial Architecture and Cellular Neighborhoods Correlate to Colorectal Cancer Outcomes

What's Popular?

Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC

SickKids' 'Rigorous' Molecular Analysis IDs Targetable Alterations, Cancer Susceptibility Mutations

Scorpion Therapeutics Launches With $108 Million in Series A Funding

Early Data in Hand, Verastem Marches Ahead With RAF-MEK Inhibitor Program in KRAS-mutated Cancers

Epic Sciences, Predicine to Offer Liquid Biopsy Service for Biopharma Customers

Sponsorships